Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness

Hepatocellular carcinoma is one of the most common cancers worldwide. Despite several efforts to elucidate hepatocellular carcinoma molecular pathogenesis, it is still not fully understood. To acquire further insights into the molecular mechanisms of hepatocellular carcinoma, we performed a systematic functional genomic approach on human HuH-7 and JHH-6 cells. The subsequent analysis of the differentially expressed genes in human specimens revealed a molecular signature of 11 genes from which we selected the LGALS1 gene, which was overexpressed in hepatocellular carcinoma. The expression analysis in humans of Galectin-1 (Gal-1), the protein encoded by LGALS1, showed a Gal-1 preferential accumulation in the stromal tissue around hepatocellular carcinoma tumors. Moreover, a significant association between increased expression of Gal-1 in hepatocellular carcinoma and the presence of metastasis was observed. Interestingly, Gal-1 overexpression resulted in an increase of cell migration and invasion. In conclusion, this study provides a portfolio of targets useful for future investigations into molecular marker-discovery studies on a large number of patients and functional assays. In addition, our data provide evidence that Gal-1 plays a role in hepatocellular carcinoma cell migration and invasion, and we suggest that further studies should be conducted to fully establish the role of Gal-1 in hepatocellular carcinoma pathogenesis and evaluate Gal-1 as a potential molecular therapeutic target.

[1]  A. Poljak,et al.  The Estrogen-responsive B Box Protein Is a Novel Regulator of the Retinoid Signal* , 2006, Journal of Biological Chemistry.

[2]  Tea Lanišnik Rižner,et al.  AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer , 2006, Molecular and Cellular Endocrinology.

[3]  V. Mazzaferro,et al.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.

[4]  R. Kiss,et al.  Galectin‐1 Modulates Human Glioblastoma Cell Migration into the Brain Through Modifications to the Actin Cytoskeleton and Levels of Expression of Small GTPases , 2002, Journal of neuropathology and experimental neurology.

[5]  Z. Tang,et al.  Hepatocellular carcinoma--cause, treatment and metastasis. , 2001, World journal of gastroenterology.

[6]  N. Zambrano,et al.  Comparative proteomic expression profile in all-trans retinoic acid differentiated neuroblastoma cell line. , 2007, Journal of proteome research.

[7]  H. Friess,et al.  Comparative Analysis of Galectins in Primary Tumors and Tumor Metastasis in Human Pancreatic Cancer , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[8]  A. Fusco,et al.  Expression of galectin‐1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors , 1995, International journal of cancer.

[9]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[10]  D. Jäger,et al.  Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Xin Wei Wang,et al.  Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma , 2007, Clinical Cancer Research.

[12]  M. Kavallaris,et al.  The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. , 2009, Cancer letters.

[13]  T. Strowitzki,et al.  Galectin fingerprinting in human endometrium and decidua during the menstrual cycle and in early gestation. , 2004, Molecular human reproduction.

[14]  L. Baum,et al.  Apoptosis of T cells mediated by galectin-1 , 1995, Nature.

[15]  Isabelle Camby,et al.  Galectins and cancer. , 2002, Biochimica et biophysica acta.

[16]  R. Kiss,et al.  Galectin‐1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma , 2001, Glia.

[17]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[18]  R. Lotan,et al.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.

[19]  I. Zagon,et al.  The biology of the opioid growth factor receptor (OGFr) , 2002, Brain Research Reviews.

[20]  Tushar Patel,et al.  Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype‐associated gene expression signatures , 2009, Cancer.

[21]  M. Dowsett,et al.  Paracrine-stimulated gene expression profile favors estradiol production in breast tumors , 2006, Molecular and Cellular Endocrinology.

[22]  H. Kinoshita,et al.  CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. , 2004, Hepato-gastroenterology.

[23]  V. Mazzaferro,et al.  Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.

[24]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[25]  G. Rabinovich,et al.  Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer , 2008, Expert opinion on biological therapy.

[26]  Hsueh-Kung Lin,et al.  Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. , 2006, Endocrine-related cancer.

[27]  Michael E. Burczynski,et al.  Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones , 2000 .

[28]  Donna M. Peehl,et al.  Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors , 2006, Molecular and Cellular Endocrinology.

[29]  M. Feitelson,et al.  Genetic mechanisms of hepatocarcinogenesis , 2002, Oncogene.

[30]  R. Bast,et al.  Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. , 1996, Human pathology.

[31]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[32]  Michiie Sakamoto,et al.  Growth and spread of hepatocellular carcinoma: A review of 240 consecutive autopsy cases , 1990, Cancer.

[33]  M. Amieva,et al.  Subcellular localization of moesin in dynamic filopodia, retraction fibers, and other structures involved in substrate exploration, attachment, and cell-cell contacts. , 1995, Experimental cell research.

[34]  V. Castronovo,et al.  Increased expression of galectin‐1 in carcinoma‐associated stroma predicts poor outcome in prostate carcinoma patients , 2001, The Journal of pathology.

[35]  K. Fujise,et al.  Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. , 1990, Hepato-gastroenterology.

[36]  Derek Y. Chiang,et al.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.

[37]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[38]  T. Yamane,et al.  Hormonal Control of α-Fetoprotein Secretion in Human Hepatoma Cell Lines Proliferating in Chemically Defined Medium , 1985 .

[39]  M. Acunzo,et al.  PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer , 2008, Journal of cellular and molecular medicine.

[40]  A. Ryo,et al.  Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements. , 2003, International journal of oncology.

[41]  Ariel,et al.  Specific inhibition of T‐cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin‐1 , 1999, Immunology.

[42]  D. Choi,et al.  Feature genes of hepatitis B virus-positive hepatocellular carcinoma, established by its molecular discrimination approach using prediction analysis of microarray. , 2004, Biochimica et biophysica acta.

[43]  H. Himmelbauer,et al.  An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division , 2004, Nature.

[44]  J. Carl Barrett,et al.  Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray , 2006, Clinical Cancer Research.

[45]  I. Zagon,et al.  The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer , 2008, Molecular Cancer.

[46]  G. Tseng,et al.  Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas , 2006, Hepatology.

[47]  A. Berchuck,et al.  Galectin-1 Accumulation in the Ovary Carcinoma Peritumoral Stroma Is Induced by Ovary Carcinoma Cells and Affects Both Cancer Cell Proliferation and Adhesion to Laminin-1 and Fibronectin , 2003, Laboratory Investigation.

[48]  T. Yamane,et al.  Hormonal control of alpha-fetoprotein secretion in human hepatoma cell lines proliferating in chemically defined medium. , 1985, Cancer research.

[49]  Tara L. Kieffer,et al.  Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .

[50]  I. Zagon,et al.  The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. , 2007, Cancer research.

[51]  E. Campo,et al.  Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. , 1997, Gastroenterology.

[52]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[53]  T. Yamane,et al.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. , 1982, Cancer research.

[54]  H Sugimura,et al.  Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. , 1996, Cancer research.

[55]  T. Yamane,et al.  Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. , 1984, Gan.

[56]  A. Iolascon,et al.  Cytokine Gene Polymorphisms in Italian Preterm Infants: Association Between Interleukin-10 –1082 G/A Polymorphism and Respiratory Distress Syndrome , 2007, Pediatric Research.

[57]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[58]  Kai Breuhahn,et al.  Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression , 2004, Cancer Research.

[59]  S. Werner,et al.  The Estrogen-responsive B Box Protein , 2002, The Journal of Biological Chemistry.

[60]  Trevor M. Penning,et al.  Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate , 2004, Steroids.

[61]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[62]  C. Hafer-Macko,et al.  Galectin-1 is expressed by thymic epithelial cells in myasthenia gravis , 1996, Glycoconjugate Journal.

[63]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[64]  Philip M. Long,et al.  Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling , 2005, Hepatology.

[65]  Ruud P. M. Dings,et al.  Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy , 2006, Proceedings of the National Academy of Sciences.

[66]  G. Rabinovich.  Galectin-1 as a potential cancer target , 2005, British Journal of Cancer.

[67]  Hsiao-Chin Hong,et al.  Galectin-1-Mediated Tumor Invasion and Metastasis, Up-Regulated Matrix Metalloproteinase Expression, and Reorganized Actin Cytoskeletons , 2009, Molecular Cancer Research.

[68]  Christa S Merzdorf,et al.  Emerging roles for zic genes in early development , 2007, Developmental dynamics : an official publication of the American Association of Anatomists.

[69]  Jérémie Rossy,et al.  Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. , 2008, The international journal of biochemistry & cell biology.

[70]  R. Lotan,et al.  Expression of galectins in head and neck squamous cell carcinoma , 1996, Head & neck.

[71]  Trevor M Penning,et al.  The roles of aldo-keto reductases in steroid hormone action. , 2004, Drug news & perspectives.

[72]  Q. Ye,et al.  A decade’s studies on metastasis of hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[73]  青鹿 佳和.  The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation , 2004 .

[74]  G. Grau,et al.  The role of adhesion molecules, &agr;v&bgr;3, &agr;v&bgr;5 and their ligands in the tumor cell and endothelial cell adhesion , 2007, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[75]  J. Tschopp,et al.  The estrogen-responsive B box protein: a novel enhancer of interleukin-1β secretion , 2006, Cell Death and Differentiation.

[76]  R. Versteeg,et al.  Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness , 2009, Oncogene.

[77]  Stefano Iacobelli,et al.  90K (Mac-2 BP) and galectins in tumor progression and metastasis , 2004, Glycoconjugate Journal.

[78]  Gabriel A. Rabinovich,et al.  Galectins as modulators of tumour progression , 2005, Nature Reviews Cancer.

[79]  G. Benvenuto,et al.  Galectin‐1 and galectin‐3 expression in human bladder transitional‐cell carcinomas , 1999, International journal of cancer.

[80]  K J Millen,et al.  The ZIC gene family in development and disease , 2005, Clinical genetics.

[81]  N. Huh,et al.  Expression of developmentally regulated endothelial cell locus 1 was induced by tumor-derived factors including VEGF. , 2005, Biochemical and biophysical research communications.

[82]  N. Berger,et al.  Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. , 1992, Oncogene.

[83]  J. Hirabayashi,et al.  Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. , 2001, Human pathology.

[84]  K. Mishima,et al.  Expression of galectin‐1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin‐1 inhibits the growth of 9 glioma cells , 2000, Journal of neuroscience research.

[85]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[86]  M. Kudo,et al.  Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009) , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[87]  E. Nakakura,et al.  Management of hepatocellular carcinoma. , 2000, Oncology.

[88]  Benhur Lee,et al.  Galectin-1 Co-clusters CD43/CD45 on Dendritic Cells and Induces Cell Activation and Migration through Syk and Protein Kinase C Signaling* , 2009, The Journal of Biological Chemistry.

[89]  E. Jung,et al.  Galectin‐1 expression in cancer‐associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer , 2007, International journal of cancer.

[90]  V. Castronovo,et al.  Differential expression of Galectin‐1 and Galectin‐3 during first trimester human embryogenesis , 1997, Developmental dynamics : an official publication of the American Association of Anatomists.

[91]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[92]  S. Barondes,et al.  Evidence for export of a muscle lectin from cytosol to extracellular matrix and for a novel secretory mechanism , 1990, The Journal of cell biology.

[93]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[94]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[95]  V. Castronovo,et al.  Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell–cell adhesion , 2004, Angiogenesis.

[96]  C. L. Jackson,et al.  Turning on ARF: the Sec7 family of guanine-nucleotide-exchange factors. , 2000, Trends in cell biology.